Tenofovir Plasma Trough Concentrations in People Living with HIV Treated with Tenofovir Disoproxyl Fumarate: Antiretroviral Class or Individual Drug Effect?

Ther Drug Monit. 2023 Apr 1;45(2):282-284. doi: 10.1097/FTD.0000000000001072. Epub 2023 Jan 10.

Authors

Dario Cattaneo¹, Stefano Bonora², Paola Meraviglia³, Stefania Vimercati⁴, Spinello Antinori³, Cristina Gervasoni³

Affiliations

¹ Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
² Department of Medical Sciences, School of Infectious and Tropical Diseases, University of Torino, Amedeo di Savoia Hospital, Torino, Italy.
³ Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
⁴ Pharmaceutical Department, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.

PMID: 36728343
DOI: 10.1097/FTD.0000000000001072

No abstract available

Publication types

Letter

MeSH terms

Anti-HIV Agents* / therapeutic use
Anti-Retroviral Agents / therapeutic use
HIV Infections* / drug therapy
Humans
Tenofovir / therapeutic use

Substances

Tenofovir
Anti-Retroviral Agents
Anti-HIV Agents